HMGB1, TLR and RAGE: A functional tripod that leads to diabetic inflammation

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 8, 2011, Pages 1023-1035

  Nogueira Machado, José Augusto ^a   Volpe, Caroline Maria De Oliveira ^a   Veloso, Clara Araujo ^a   Chaves, Miriam Martins ^b  

^a Instituto de Ensino e Pesquisa da Santa Casa de Belo Horizonte   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Diabetes; HMGB1; Inflammation; Innate immunity; RAGE; Toll like receptors

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DIABETES MELLITUS; HUMAN; INNATE IMMUNITY; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANTIGENS, NEOPLASM; DIABETES MELLITUS; HMGB1 PROTEIN; HUMANS; INFLAMMATION; MITOGEN-ACTIVATED PROTEIN KINASES; TOLL-LIKE RECEPTORS;

EID: 79960238978     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.575360     Document Type: Review

References (125)

1. Nogueira-Machado JA, Chaves MM. From hyperglycemia to AGE-RAGE interaction on the cell surface: a dangerous metabolic route for diabetic patients. Expert Opin Ther Targets 2008;12:871-82 (Pubitemid 352003326)
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53 (Pubitemid 38579764)
3. Rauvala H, Rouhiainen A. RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease. Curr Mol Med 2007;7:725-34
4. Kim JJ, Sears DD. TLR4 and insulin resistance. Gastroenterol Res Pract 2010;2010:1-11
5. Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 2000;16:192-201 (Pubitemid 30410275)
6. Muller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002;45:805-12
7. Pickup JC, Crook MA. Crook, Is type 2 diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41:1241-8 (Pubitemid 28449093)
8. Syed MA, Barinas-Mitchell E, Pietropaolo SL, et al. Is type 2 diabetes a chronic inflammatory/autoimmune disease? Diabetes Nutr Metab 2002;15:68-83 (Pubitemid 34546200)
9. Tracey KJ. Fat meets the cholinergic antiinflammatory pathway. J Exp Med 2005;202:1017-21
10. Klune JR, Dhupar R, Cardinal J, et al. HMGB1: endogenous danger signaling. Mol Med 2008;14:476-84
11. Mantell LL, Parrish WR, Ulloa L. Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 2006;25:4-11
12. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004;63:582-92 (Pubitemid 39078671)
13. Dasu MR, Devaraj S, Ling Z, et al. High glucose induces Toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 2008;57:3090-8
14. Han J, Zong J, Wei W, et al. Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes 2008;57:2118-27
15. Matsuoka N, Itoh T, Watari H, et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest 2010;120:735-43
16. Agresti A, Bianchi ME. HMGB proteins and gene expression. Curr Opin Genet Dev 2003;13:170-8 (Pubitemid 36369741)
17. Bustin M. Chromatin unfolding and activation by HMGN*chromosomal proteins. Trends Biochem Sci 2001;26:431-7 (Pubitemid 32607485)
18. Thomas JO. HMG1 and 2: architectural DNA-binding proteins. Biochem Soc Trans 2001;29:395-401
19. Li J, Kokkola R, Tabibzadeh S, et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 2003;9:37-45 (Pubitemid 36667690)
20. Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004;173:307-13 (Pubitemid 38797355)
21. Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004;101:296-301 (Pubitemid 38084244)
22. Yang H, Hreggvidsdottir HS, Palmblad K, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010;107:11942-7
23. Bell CW, Jiang W, Reich CF, et al. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006;291:C1318-25
24. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-42 (Pubitemid 40516158)
25. Rovere-Querini P, Capobianco A, Scaffidi P, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004;5(8):825-30 (Pubitemid 39199174)
26. Pisetsky DS, Erlandsson-Harris H, Andersson U. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 2008;10:209
27. Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003;22:5551-60 (Pubitemid 37279964)
28. Devaraj S, Dasu MR, Park SH, et al. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 2009;52:1665-8
29. Pachydaki SI, Tari SR, Lee SE, et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res 2006;82(5):807-15 (Pubitemid 43170881)
30. Dasu MR, Devaraj S, Park S, et al. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010;33:861-8
31. Hagiwara S, Iwasaka H, Hasegawa A, et al. Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit Care Med 2008;36:2407-13
32. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006;290:C917-24
33. Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279:7370-7 (Pubitemid 38294612)
34. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008;11:91-9
35. van Zoelen MA, Yang H, Florquin S, et al. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009;31:280-4
36. Branco-Madeira F, Lambrecht BN. Lambrecht, High mobility group box-1 recognition: the beginning of a RAGEless era? EMBO Mol Med 2010;2:193-5
37. Kokkola R, Andersson A, Mullins G, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005;61:1-9 (Pubitemid 40188342)
38. Park JS, Arcaroli J, Yum HK, et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 2003;284:C870-9 (Pubitemid 36336943)
39. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999;274:19919-24
40. Li J, Wang H, Mason JM, et al. Recombinant HMGB1 with cytokine-stimulating activity. J Immunol Methods 2004;289:211-23 (Pubitemid 38900918)
41. Rouhiainen A, Tumova S, Valmu L, et al. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol 2007;81:49-58 (Pubitemid 46021252)
42. Sha Y, Zmijewski J, Xu Z, et al. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008;180:2531-7
43. Youn JH, Oh YJ, Kim ES, et al. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol 2008;180:5067-74
44. Zimmermann K, Volkel D, Pable S, et al. Native versus recombinant high-mobility group B1 proteins: functional activity in vitro. Inflammation 2004;28:221-9 (Pubitemid 41449422)
45. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889-97 (Pubitemid 24196599)
46. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192:565-70 (Pubitemid 30666257)
47. Andrassy M, Volz HC, Igwe JC, et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008;117:3216-26
48. Bruchfeld A, Qureshi AR, Lindholm B, et al. High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med 2008;14:109-15 (Pubitemid 351481841)
49. Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med 2004;21:203-7 (Pubitemid 38299611)
50. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005;48:1038-50 (Pubitemid 40909636)
51. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002;168:554-61 (Pubitemid 34049553)
52. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801 (Pubitemid 43261452)
53. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216 (Pubitemid 34293424)
54. Lin L. RAGE on the Toll Road? Cell Mol Immunol 2006;3:351-8
55. Devaraj S, Dasu MR, Rockwood J, et al. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008;93:578-83 (Pubitemid 351240834)
56. Tobias PS, Curtiss LK. Toll-like receptors in atherosclerosis. Biochem Soc Trans 2007;35:1453-5
57. Buraczynska M, Baranowicz-Gaszczyk I, Tarach J, et al. Toll-like receptor 4 gene polymorphism and early onset of diabetic retinopathy in patients with type 2 diabetes. Hum Immunol 2009;70:121-4
58. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-25 (Pubitemid 44684486)
59. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511 (Pubitemid 38931765)
60. Yamamoto M, Takeda K. Current views of toll-like receptor signaling pathways. Gastroenterol Res Pract 2010;2010:240365
61. Burns K, Martinon F, Esslinger C, et al. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem 1998;273:12203-9 (Pubitemid 28240584)
62. Wesche H, Henzel WJ, Shillinguaw W, et al. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997;7:837-47 (Pubitemid 28064897)
63. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, et al. Mal (MyD88-adapterlike) is required for Toll-like receptor-4 signal transduction. Nature 2001;413:78-83 (Pubitemid 32843491)
64. Yamamoto M, Sato S, Mori K, et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002;169:6668-72 (Pubitemid 36899248)
65. Fitzgerald KA, Rowe DC, Barnes BJ, et al. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 2003;198:1043-55 (Pubitemid 37248620)
66. Carty M, Goodbody R, Schroder M, et al. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol 2006;7:1074-81 (Pubitemid 44420652)
67. Kumar A, Periyannan GR, Narayanan B, et al. Experimental evidence for a metallohydrolase mechanism in which the nucleophile is not delivered by a metal ion: EPR spectrokinetic and structural studies of aminopeptidase from Vibrio proteolyticus. Biochem J 2007;403:527-36 (Pubitemid 46706981)
68. Kawai T, Adachi O, Ogawa T, et al. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999;11:115-22 (Pubitemid 29359962)
69. Kawai T, Takeuchi O, Fujita T, et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 2001;167:5887-94 (Pubitemid 33062783)
70. Rassa JC, Meyers JL, Zhang Y, et al. Murine retroviruses activate B cells via interaction with toll-like receptor 4. Proc Natl Acad Sci USA 2002;99:2281-6 (Pubitemid 34169052)
71. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-7 (Pubitemid 27334820)
72. Ojaniemi M, Liljeroos M, Harju K, et al. TLR-2 is upregulated and mobilized to the hepatocyte plasma membrane in the space of Disse and to the Kupffer cells TLR-4 dependently during acute endotoxemia in mice. Immunol Lett 2006;102:158-68 (Pubitemid 43053085)
73. Chow JC, Young DW, Golenbock DT, et al. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999;274:10689-92
74. Byrd-Leifer CA, Block, EF, et al. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 2001;31:2448-57 (Pubitemid 32785364)
75. Kawasaki K, Akashi S, Shimazu R, et al. Mouse toll-like receptor 4. MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem 2000;275:2251-4 (Pubitemid 30081977)
76. Kawasaki K, Gomi K, Nishijima M. Cutting edge: Gln22 of mouse MD-2 is essential for species-specific lipopolysaccharide mimetic action of taxol. J Immunol 2001;166:11-14 (Pubitemid 32038410)
77. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001;13:114-19 (Pubitemid 32096970)
78. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76 (Pubitemid 37174535)
79. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-19 (Pubitemid 40629025)
80. Aliprantis AO, Yang RB, Weiss DS, et al. The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J 2000;19:3325-36 (Pubitemid 30428210)
81. Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999;285:732-6
82. Lien E, Sellati TJ, Yoshimura A, et al. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 1999;274:33419-25 (Pubitemid 129511647)
83. Lehner MD, Morath S, Michelsen KS, et al. Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators. J Immunol 2001;166:5161-7 (Pubitemid 32280731)
84. Schwandner R, Dziarski R, Wesche H, et al. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 1999;274:17406-9
85. Underhill DM, Ozinsky A, Smith KD, et al. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci USA 1999;96:14459-63 (Pubitemid 30000672)
86. Campos MA, Almeida IC, Takeuchi O, et al. Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol 2001;167:416-23 (Pubitemid 32567807)
87. Underhill DM, Ozinsky A, Hajjar AM, et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999;401:811-15
88. Opitz B, Schroder NWJ, Spreitzer I, et al. Toll-like receptor-2 mediates Treponema glycolipid and lipoteichoic acid-induced NF-kappaB translocation. J Biol Chem 2001;276(25):22041-7
89. Massari P, Henneke P, Ho Y, et al. Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J Immunol 2002;168(4):1533-7 (Pubitemid 34135744)
90. Hirschfeld M, Weis JJ, Toshchakov V, et al. Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect Immun 2001;69:1477-82 (Pubitemid 32187597)
91. Werts C, Tapping RI, Mathison JC, et al. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat Immunol 2001;2:346-52 (Pubitemid 33706346)
92. Arbibe L, Mira JP, Teusch N, et al. Toll-like receptor 2-mediated NF-kappaB activation requires a Rac1-dependent pathway. Nat Immunol 2000;1:533-40
93. Aomatsu K, Kato T, Fujita H, et al. Toll-like receptor agonists stimulate human neutrophil migration via activation of mitogen-activated protein kinases. Immunology 2008;123:171-80
94. Schmidt AM, Stern DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab 2000;11:368-75
95. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-109 (Pubitemid 36399105)
96. Kislinger T, Fu C, Huber B, et al. Nepsi-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999;274(44):31740-9
97. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998-5004
98. Bucciarelli LG, Wendt T, Rong L, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002;59:1117-28
99. Hofmann MA, Drury S, Hudson BI, et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002;3:123-35 (Pubitemid 38961122)
100. Schmidt AM, Yan SD, Yan SF, et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55 (Pubitemid 32946067)
101. Yamamoto Y, Kato I, Yonekura H, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261-8 (Pubitemid 32656250)
102. Myint KM, Yamamoto Y, Doi T, et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 2006;55:2510-22 (Pubitemid 44871151)
103. Yonekura H, Yakamoto Y, Sakurai S, et al. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J Pharmacol Sci 2005;97:305-11 (Pubitemid 40515743)
104. Soro-Paavonen A, Watson AMD, Li J, et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008;57:2461-9
105. Hsieh HL, Schafer BW, Sasaki N, et al. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun 2003;307:375-81 (Pubitemid 36818881)
106. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60 (Pubitemid 30337069)
107. Yan SS, Wu ZY, Zhang HP, et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 2003;9:287-93 (Pubitemid 36362783)
108. Ruan BH, Li X, Winkler AR, et al. Complement C3a, CpG oligos, and DNA/C3a complex stimulate IFN-alpha production in a receptor for advanced glycation end product-dependent manner. J Immunol 2010;185:4213-22
109. Yamamoto Y, Harashima A, Saito H, et al. Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J Immunol 2011;186:3248-57
110. Yan SF, Ravichandran R, Naka Y, et al. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003;93:1159-69 (Pubitemid 37543056)
111. Bierhaus A, Hofmann MA, Ziegler R, et al. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998;37:586-600 (Pubitemid 28231153)
112. Schmidt AM, Hori O, Cao R, et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996;45(Suppl 3):S77-80
113. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993;143:1699-712 (Pubitemid 24058273)
114. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-91 (Pubitemid 26282167)
115. Cooke CL, Brockelsby JC, Baker PN, et al. The receptor for advanced glycation end products (RAGE) is elevated in women with preeclampsia. Hypertens Pregnancy 2003;22:173-84 (Pubitemid 37521369)
116. Lander HM, Tauras JM, Ogiste JS, et al. Activation of the receptor for advanced glycation end products triggers a p21ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272:17810-14 (Pubitemid 27311222)
117. Sakaguchi T, Yan SF, Yan SD, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003;111:959-72 (Pubitemid 36397472)
118. Hudson BI, Kalea AZ, Del Mar Arriero, et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem 2008;283:34457-68
119. Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J Leukoc Biol 2009;86:505-12
120. Xu Y, Toure F, Qu W, et al. Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J Biol Chem 2010;285:23233-40
121. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009;52:2251-63
122. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001;50:2792-808 (Pubitemid 33733131)
123. Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 2006;7:985-91 (Pubitemid 44756124)
124. Stern DM, Yan SD, Yan SF, et al. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002;1:1-15 (Pubitemid 38340348)
125. Bhattacharjee RN, Akira S. Toll-like receptor signaling: emerging opportunities in human diseases and medicine. Curr Immunol Rev 2005;1:81-90